The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases
Open accessAbstract
Phosphodiesterase 4 (PDE4) is a key enzyme in the degradation of cyclic adenosine monophosphate and is centrally involved in the cytokine production of inflammatory cells, angiogenesis, and the functional properties of other cell types such as keratinocytes. In this review article, apremilast, a novel small molecule inhibitor of PDE4, is introduced. Apremilast has profound anti-inflammatory properties in animal models of inflammatory disease, as well as human chronic inflammatory diseases such as psoriasis and psoriatic arthritis. Apremilast blocks the synthesis of several pro-inflammatory cytokines and chemokines, such as tumor necrosis factor alpha, interleukin 23, CXCL9, and CXCL10 in multiple cell types. In contrast to the biologics, which neutralize pro-inflammatory mediators at the protein level, apremilast modulates production of these mediators at the level of mRNA expression. Apremilast also interferes with the production of leukotriene B4, inducible nitric oxide synthase, and matrix metalloproteinase and reduces complex inflammatory processes, such as dendritic cell infiltration, epidermal skin thickening, and joint destruction. As this novel PDE4 inhibitor interferes with several key processes of inflammation, it may emerge as a promising new drug for the treatment of chronic inflammatory diseases such as those of the skin and the joints.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robichaud, A., Stamatiou, P. B., Jin, S.-L. C., Lachance, N., MacDonald, D., Laliberté, F., Liu, S., Huang, Z., Conti, M., & Chan, C.-C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15506 · Cited by 267 · cited 1×
“The PDE4D isozyme has been associated with the behavioral correlate of emesis in mice [Robichaud et al. 2002].”
Background
Cited by
Neutrophils as emerging therapeutic targets
Németh, T., Sperandio, M., & Mócsai, A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0054-z · Cited by 653
Paul, C., Cather, J., Gooderham, M., Poulin, Y., Mrowietz, U., Ferrandiz, C., Crowley, J., Hu, C., Stevens, R. M., Shah, K., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14164 · Cited by 484
Self-citationApremilast mechanism of action and application to psoriasis and psoriatic arthritis
Schafer, P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.001 · Cited by 439
Self-citationThe cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases
Raker, V. K., Becker, C., & Steinbrink, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00123 · Cited by 319
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Metadata
- Authors
- Schett, G., Sloan, V. S., Stevens, R. M., & Schafer, P.
- Venue
- Therapeutic Advances in Musculoskeletal Disease
- Publisher
- SAGE Publications
- Published
- 2010-08-16
- Volume
- 2
- Issue
- 5
- Pages
- 271-278
- ISSN
- 1759-720X (ISSN-L)
- 1759-7218
- OpenAlex
- W2133309045
- Cited by
- 171
- References
- 1
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. https://app.cochat.ai/papers/10.1177/1759720x10381432
- The paper
- Schett, G., Sloan, V. S., Stevens, R. M., & Schafer, P. (2010). Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Therapeutic Advances in Musculoskeletal Disease. https://doi.org/10.1177/1759720x10381432
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.